Tishcon Corp. Receives Orphan Drug Designations for Coenzyme Q10 in the Treatment of Pediatric Congestive Heart Failure and Huntington's Disease

TISHCON CORP. (April 16, 2004 - Westbury, NY) announced that the U.S. FDA has granted the firm Orphan Drug Designations for UBIQUINOL (Coenzyme Q10) in the treatment of :
1- Pediatric Congestive Heart Failure, and
2- Huntington's Disease

Tishcon Corp. was also granted an Orphan Drug Designation for Coenzyme Q10 (Ubi-Q-Gel®) in the treatment of Mitochondrial Cytopathies, in 1999.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.